Respiratory diseases are one of the prime topics of concern in the current era due to improper
diagnostics tools. Gene-editing therapy, like Clustered regularly interspaced palindromic repeats-
associated nuclease 9 (CRISPR/Cas9), is gaining popularity in pulmonary research, opening
up doors to invaluable insights on underlying mechanisms. CRISPR/Cas9 can be considered as a
potential gene-editing tool with a scientific community that is helping in the advancement of knowledge
in respiratory health and therapy. As an appealing therapeutic tool, we hereby explore the advanced
research on the application of CRISPR/Cas9 tools in chronic respiratory diseases such as
lung cancer, Acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). We also address
the urgent need to establish this gene-editing tool in various other lung diseases such as asthma,
Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). The present
review introduces CRISPR/Cas9 as a worthy application in targeting epithelial-mesenchymal
transition and fibrinolytic system via editing specific genes. Thereby, based on the efficiency of
CRISPR/Cas9, it can be considered as a promising therapeutic tool in respiratory health research.
Lipid Fluidity as an Essential Therapeutic Tool for Cell Pathology
